Selected article for: "disease progression and potential target"
Author: Tay, Matthew Zirui; Poh, Chek Meng; Rénia, Laurent; MacAry, Paul A.; Ng, Lisa F. P.
Title: The trinity of COVID-19: immunity, inflammation and intervention
  • Cord-id: rcdoewwv
  • Document date: 2020_4_28
    • ID: rcdoewwv
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiology of SARS-CoV-2 infection. We describe the inter
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiology of SARS-CoV-2 infection. We describe the interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression. From nascent reports describing SARS-CoV-2, we make inferences on the basis of the parallel pathophysiological and immunological features of the other human coronaviruses targeting the lower respiratory tract — severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Finally, we highlight the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation.

    Search related documents:
    Co phrase search for related documents
    • aberrant inflammatory response and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • aberrant inflammatory response and adaptive immune response: 1
    • aberrant inflammatory response and lung damage: 1
    • aberrant inflammatory response and lung infection: 1, 2, 3, 4
    • aberrant inflammatory response and lung inflammation: 1, 2
    • aberrant inflammatory response and lung injury: 1, 2
    • active infection and acute lung injury: 1, 2, 3, 4, 5
    • active infection and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • active infection and adaptive immune response: 1, 2, 3, 4, 5
    • active infection and low respiratory: 1, 2, 3, 4
    • active infection and low respiratory tract: 1
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • active infection and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • active infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active infection and lung injury reduce: 1
    • active infection and machine learning: 1, 2